Floatz logo

Ipilimumab

Refractory Germ-cell

Dana-Farber Cancer Institutemonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Refractory Germ-cell cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BB
ETOPOSIDE
Nabil Adra
Phase 3BB
Pembrolizumab
Hoffmann-La Roche
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Hoffmann-La Roche
Phase 3BB

View all 48 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →